Turning $100,000 into $1 million doesn't happen overnight. It requires years, often decades, of owning businesses that can compound earnings at high rates while reinvesting intelligently.
That narrows the field dramatically.
For me, the most realistic path isn't chasing speculative moonshots, but backing high-quality companies with long growth runways, strong competitive advantages, and management teams that consistently execute.
Here are two ASX stocks that I believe fit that description.
HUB24 Ltd (ASX: HUB)
HUB24 has quietly become one of the most powerful compounders on the ASX. Over the past 10 years, its shares have achieved an incredible average total return of 35.85% per year. That would have turned a $10,000 investment in 2015 into more than $200,000 today.
Although it is unlikely to achieve the same feat again through to 2035, I believe it can outperform the broader market.
HUB24 operates a leading wealth platform that sits between financial advisers and their clients' investments. As more Australians seek professional advice, driven by ageing demographics, superannuation complexity, and intergenerational wealth transfer, the demand for high-quality platforms continues to grow.
What makes HUB24 particularly attractive is its operating leverage. As funds under administration rise, its revenue grows faster than costs, allowing margins to expand over time. That's exactly the kind of business dynamic long-term investors should look for.
The company has also built a broader ecosystem through complementary technology businesses, deepening adviser relationships and increasing switching costs. Importantly, this growth hasn't come at the expense of balance sheet strength or discipline.
HUB24 shares are not cheap, but they deserve their premium, in my opinion. If it continues to gain market share and scale efficiently, I think it has the potential to deliver the kind of long-term returns needed to turn a six-figure investment into something even more meaningful.
Pro Medicus Ltd (ASX: PME)
If HUB24 represents compounding through financial infrastructure, Pro Medicus represents compounding through technological superiority.
This ASX stock is a quick-growing provider of enterprise medical imaging software to hospitals and healthcare systems. Its Visage platform is known for speed, scalability, and efficiency, and once installed, it tends to become deeply embedded in hospital workflows.
That leads to exceptionally sticky customers, long-term contracts, and recurring revenue.
What stands out to me is Pro Medicus' combination of very high margins, strong cash generation, and a long growth runway. Healthcare imaging volumes continue to rise, data sizes are exploding, and hospitals are under pressure to improve efficiency. These are all trends that play directly into Pro Medicus' strengths.
Like HUB24, Pro Medicus is not a bargain stock. But valuation alone doesn't create wealth; business quality does. I would rather own a high-quality ASX stock at a fair price than a poor-quality stock at a cheap price. Over time, companies that consistently grow earnings at high rates can justify premium valuations and still deliver outstanding shareholder returns. I expect this to be the case over the coming 10 years and beyond.
